TY - JOUR AU - Nyla A. Heerema, AU - Natarajan Muthusamy, AU - Qiuhong Zhao, AU - Amy S. Ruppert, AU - Heather Breidenbach, AU - Leslie A. Andritsos, AU - Michael R. Grever, AU - Kami J. Maddocks, AU - Jennifer Woyach, AU - Farrukh Awan, AU - Meixiao Long, AU - Amber Gordon, AU - Caitlin Coombes, AU - John C. Byrd, PY - 2020/05/15 Y2 - 2024/03/19 TI - Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia JF - Haematologica JA - haematol VL - 106 IS - 6 SE - Articles DO - 10.3324/haematol.2018.212571 UR - https://haematologica.org/article/view/9754 SP - 1608-1615 AB - Mutations of the IGH variable region in patients with chronic lymphocytic leukemia (CLL) are associated with a favorable prognosis. Cytogenetic complexity (>3 unrelated aberrations) and translocations have been associated with an unfavorable prognosis. While mutational status of IGHV is stable, cytogenetic aberrations frequently evolve. However, the relationships of these features as prognosticators at diagnosis are unknown. We examined the CpG-stimulated metaphase cytogenetic features detected within one year of diagnosis of CLL and correlated these features with outcome and other clinical features including IGHV. Of 329 untreated patients, 53 (16.1%) had a complex karyotype (16.1%), and 85 (25.8%) had a translocation. Median time to first treatment (TFT) was 47 months. In univariable analyses, significant risk factors for shorter TFT (p3.5, log-transformed WBC, unmutated IGHV, complex karyotype, translocation, and FISH for trisomy 8, del(11q) and del(17p). In multivariable analysis, there was significant effect modification of IGHV status on the relationship between translocation and TFT (p=0.002). In IGHV mutated patients, those with a translocation had over 3.5 times higher risk of starting treatment than those without a translocation (p